
Opinion|Videos|March 18, 2025
An Overview of Treatment Approaches for BPDCN
Author(s)Marlise R. Luskin, MD, MSCE
An expert discusses how, historically, blastic plasmacytoid dendritic cell neoplasm (BPDCN) was treated with regimens for acute leukemia or lymphoma. Current NCCN guidelines recommend intensive multiagent chemotherapy followed by allogeneic stem cell transplantation, when possible, with targeted therapies like tagraxofusp now available for specific cases.
Advertisement
Video content above is prompted by the following:
- Briefly, what have patients historically been treated with when diagnosed with BPDCN?
- Please provide an overview of the current treatment options per NCCN guidelines.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
3
FDA Oncology Update January 2026: New Horizons in Precision Medicine
4
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
5



















